OrganiGram Holdings Inc. (OGI)
USD 1.15
(0.88%)
USD 1.15
(0.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -30.15 Million CAD | 53.72% |
| 2022 | -65.15 Million CAD | -29.27% |
| 2021 | -50.4 Million CAD | -163.75% |
| 2020 | 79.07 Million CAD | 3812.47% |
| 2019 | 2.02 Million CAD | -95.42% |
| 2018 | 44.1 Million CAD | 2725.23% |
| 2017 | 1.56 Million CAD | 165.97% |
| 2016 | -2.36 Million CAD | -169.9% |
| 2015 | 3.38 Million CAD | 2570.98% |
| 2014 | -136.99 Thousand CAD | 13.17% |
| 2013 | -157.78 Thousand CAD | 50.79% |
| 2012 | -320.59 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -41.67 Million CAD | -43.01% |
| 2024 Q3 | -79.15 Million CAD | -10.42% |
| 2024 Q2 | -71.68 Million CAD | -72.0% |
| 2023 Q3 | -52.53 Million CAD | 14.76% |
| 2023 Q1 | -69.85 Million CAD | -7.21% |
| 2023 Q2 | -61.63 Million CAD | 11.77% |
| 2023 FY | -29.14 Million CAD | 55.27% |
| 2023 Q4 | -29.14 Million CAD | 44.52% |
| 2022 Q1 | -96.55 Million CAD | -91.56% |
| 2022 Q2 | -74.44 Million CAD | 22.9% |
| 2022 Q3 | -119.75 Million CAD | -60.86% |
| 2022 FY | -65.15 Million CAD | -29.27% |
| 2022 Q4 | -65.15 Million CAD | 45.59% |
| 2021 Q2 | -57.6 Million CAD | -480.34% |
| 2021 Q3 | -53.16 Million CAD | 7.71% |
| 2021 Q4 | -50.4 Million CAD | 5.19% |
| 2021 FY | -50.4 Million CAD | -163.75% |
| 2021 Q1 | 15.14 Million CAD | -80.85% |
| 2020 Q3 | 43.55 Million CAD | -5.1% |
| 2020 Q2 | 45.89 Million CAD | -12.42% |
| 2020 Q1 | 52.4 Million CAD | 2492.97% |
| 2020 Q4 | 79.07 Million CAD | 81.55% |
| 2020 FY | 79.07 Million CAD | 3812.47% |
| 2019 Q4 | 2.02 Million CAD | -11.32% |
| 2019 FY | 2.02 Million CAD | -95.42% |
| 2019 Q3 | 2.27 Million CAD | -95.42% |
| 2019 Q2 | 49.8 Million CAD | -27.36% |
| 2019 Q1 | 68.55 Million CAD | 55.46% |
| 2018 Q4 | 44.1 Million CAD | -34.25% |
| 2018 FY | 44.1 Million CAD | 2725.23% |
| 2018 Q1 | -4.22 Million CAD | -370.82% |
| 2018 Q2 | 42.56 Million CAD | 1107.01% |
| 2018 Q3 | 67.07 Million CAD | 57.57% |
| 2017 Q1 | 1.91 Million CAD | 180.96% |
| 2017 Q2 | 2.31 Million CAD | 20.86% |
| 2017 FY | 1.56 Million CAD | 165.97% |
| 2017 Q3 | 863.44 Thousand CAD | -62.71% |
| 2017 Q4 | 1.56 Million CAD | 80.78% |
| 2016 FY | -2.36 Million CAD | -169.9% |
| 2016 Q3 | 5.64 Million CAD | -15.28% |
| 2016 Q2 | 6.65 Million CAD | 27.03% |
| 2016 Q1 | 5.24 Million CAD | 54.85% |
| 2016 Q4 | -2.36 Million CAD | -141.95% |
| 2015 Q1 | 1.17 Million CAD | 120.46% |
| 2015 FY | 3.38 Million CAD | 2570.98% |
| 2015 Q4 | 3.38 Million CAD | 66.17% |
| 2015 Q3 | 2.03 Million CAD | 18.19% |
| 2015 Q2 | 1.72 Million CAD | 47.13% |
| 2014 Q1 | -143.41 Thousand CAD | -2.14% |
| 2014 Q3 | -136.99 Thousand CAD | 4.02% |
| 2014 Q4 | -5.72 Million CAD | -4080.15% |
| 2014 Q2 | -142.73 Thousand CAD | 0.47% |
| 2014 FY | -136.99 Thousand CAD | 13.17% |
| 2013 Q2 | -164.08 Thousand CAD | 20.96% |
| 2013 Q1 | -207.58 Thousand CAD | 25.3% |
| 2013 FY | -157.78 Thousand CAD | 50.79% |
| 2013 Q4 | -140.4 Thousand CAD | 11.01% |
| 2013 Q3 | -157.78 Thousand CAD | 3.84% |
| 2012 Q4 | -277.91 Thousand CAD | 13.31% |
| 2012 Q3 | -320.59 Thousand CAD | 16.71% |
| 2012 Q2 | -384.93 Thousand CAD | -178.94% |
| 2012 Q1 | -138 Thousand CAD | 0.0% |
| 2012 FY | -320.59 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 132.012% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 140.237% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 106.928% |
| Cosmos Health Inc. | 8.59 Million USD | 451.052% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -267.177% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 106.575% |
| Cronos Group Inc. | -663.32 Million USD | 95.454% |
| Incannex Healthcare Limited | -5.48 Million USD | -449.827% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -106.959% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 124.74% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -939.419% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -92.892% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -92.892% |
| SCYNEXIS, Inc. | -19.35 Million USD | -55.855% |
| Safety Shot Inc | -2.28 Million USD | -1220.186% |
| Theratechnologies Inc. | 24.87 Million USD | 221.258% |
| Alpha Teknova, Inc. | 1.97 Million USD | 1627.761% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 15392.406% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 106.969% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -1096.746% |
| Dynavax Technologies Corporation | 106.63 Million USD | 128.282% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 104.838% |
| Radius Health, Inc. | 359.28 Million USD | 108.394% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -219.818% |
| Alvotech | 1.06 Billion USD | 102.834% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 76.949% |
| SIGA Technologies, Inc. | -148.68 Million USD | 79.716% |
| Shineco, Inc. | 29.29 Million USD | 202.962% |
| Silver Spike Investment Corp. | -32.61 Million USD | 7.524% |
| Journey Medical Corporation | -9.7 Million USD | -210.619% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -495.963% |
| Embecta Corp. | 1.31 Billion USD | 102.299% |
| Harrow Health, Inc. | 116.41 Million USD | 125.905% |
| Procaps Group, S.A. | 242.93 Million USD | 112.414% |
| Biofrontera Inc. | 4.05 Million USD | 843.54% |
| DURECT Corporation | -7.65 Million USD | -294.016% |
| PainReform Ltd. | -7.95 Million USD | -279.346% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 10.049% |
| OptiNose, Inc. | 58.06 Million USD | 151.938% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -481.524% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 300.879% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 28322.237% |
| ProPhase Labs, Inc. | 19.23 Million USD | 256.82% |
| Phibro Animal Health Corporation | 454.84 Million USD | 106.63% |
| Procaps Group S.A. | 242.93 Million USD | 112.414% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 919.956% |
| Viatris Inc. | 17.13 Billion USD | 100.176% |
| Rockwell Medical, Inc. | 4.45 Million USD | 776.795% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -518.372% |
| Tilray Brands, Inc. | 158.97 Million USD | 118.97% |
| PetIQ, Inc. | 351.93 Million USD | 108.569% |
| Talphera, Inc. | -5.72 Million USD | -427.146% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 117.01% |
| Alimera Sciences, Inc. | 55.3 Million USD | 154.526% |
| Assertio Holdings, Inc. | -32.52 Million USD | 7.289% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -1925.764% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 815.153% |
| Hempacco Co., Inc. | 13.61 Million USD | 321.511% |
| Alvotech | 1.06 Billion USD | 102.834% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 68.816% |
| Kamada Ltd. | -46.43 Million USD | 35.048% |
| Currenc Group, Inc. | -16.57 Million USD | -81.969% |
| Indivior PLC | -33.95 Million USD | 11.175% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 11673.68% |
| Flora Growth Corp. | -713 Thousand USD | -4129.734% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -267.177% |
| Evolus, Inc. | 63.7 Million USD | 147.338% |
| HUTCHMED (China) Limited | -197.45 Million USD | 84.727% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 106.295% |
| Akanda Corp. | 3.9 Million USD | 872.309% |